Field Notes · Research Findings

After a single psilocybin dose, veterans' anxiety, quality of life, and functioning improved — but the gains largely tracked their depression improvement rather than standing on their own.

A 2026 analysis looked at whether a single psilocybin dose helped veterans' anxiety, quality of life, and functioning — beyond its effect on their depression.

Plain-language summary

This exploratory analysis examined whether a single 25 mg psilocybin dose helped veterans with treatment-resistant depression across anxiety, quality of life, functioning, and PTSD — beyond its effect on depression itself. Anxiety fell 59% by three weeks (sustained to a year), and quality of life and functioning also improved. But once the researchers accounted for how much depression had improved, those other gains were no longer statistically significant — suggesting they moved together with the lift in depression rather than independently. It's a small, open-label study.

PsilocybinAnxiety · QoL · PTSDOpen-label (secondary analysis)n = 15veterans3 wk to 12 moPeer-reviewed
Summary

This exploratory secondary analysis of an open-label psilocybin trial in veterans with treatment-resistant depression (n=15; 10 completed 12 months) examined anxiety (GAD-7), quality of life (Q-LES-Q-SF), functioning (WSAS), and PTSD (PCL-5) after a single 25 mg dose. GAD-7 fell 59% at Week 3 (sustained to 12 months), Q-LES-Q rose 24% at Week 3, WSAS improved 46% at Week 3. Crucially, these effects were no longer statistically significant after adjusting for concurrent depression improvement.

Appraisal

The depression-adjustment finding is the key nuance: the anxiety, quality-of-life, and functioning gains largely co-varied with depression rather than being independent. As a small (n=15), open-label, uncontrolled secondary analysis it is exploratory; the authors note the small sample and open-label design.

Placement — cross-study context, each claim sourced

This draws on the first psilocybin trial in U.S. veterans (Ellis et al., 2024), whose 12-month follow-up showed the antidepressant benefit itself waned across the year (Ellis et al., 2025). Together they temper enthusiasm: the acute gains are real but may be depression-driven and not durable.

Kelly, C. M., Fradet, M., Bostian, C. M., Donnelly, A., Ellis, S., Ostacher, M., Aaronson, S., & Suppes, T. (2026). Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression. Journal of Affective Disorders, 412, 122063.
Read the full paper →